Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD
· Real-Time Price · USD
1.29
0.04 (3.20%)
At close: May 01, 2025, 3:59 PM
1.29
-0.39%
After-hours: May 01, 2025, 07:56 PM EDT
Company Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company.
The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device.
The company was incorporated in 2018 and is based in New York, New York.
Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc.

Country | United States |
IPO Date | Oct 14, 2021 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 72 |
CEO | Dr. Lishan Aklog M.D. |
Contact Details
Address: One Grand Central Place New York, New York United States | |
Website | https://www.luciddx.com |
Stock Details
Ticker Symbol | LUCD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001799011 |
CUSIP Number | 54948X109 |
ISIN Number | US54948X1090 |
Employer ID | 82-5488042 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Lishan Aklog M.D. | Chairman & Chief Executive Officer |
Dennis M. McGrath CPA | Chief Financial Officer |
Shaun M. O'Neill M.B.A. | President & Chief Operating Officer |
Dr. Amitabh Chak M.D. | Co-Founder & Strategic Advisor |
Dr. Brian J. deGuzman M.D. | Chief Technology & Compliance Officer |
Dr. Joseph Willis M.D. | Co-founder & Strategic Advisor |
Dr. Sanford D. Markowitz M.D., Ph.D. | Co-Founder & Strategic Advisor |
Dr. Suman M. Verma M.D., Ph.D. | Chief Scientific Officer |
Helen Moinova Ph.D. | Co-Founder & Strategic Advisor |
Michael Adam Gordon | General Counsel & Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 30, 2025 | DEFA14A | Filing |
Apr 30, 2025 | ARS | Filing |
Apr 30, 2025 | DEF 14A | Filing |
Apr 25, 2025 | 8-K | Current Report |
Apr 18, 2025 | PRE 14A | Filing |
Apr 11, 2025 | 8-K | Current Report |
Apr 10, 2025 | 424B5 | Filing |
Apr 10, 2025 | 8-K | Current Report |
Apr 09, 2025 | 424B5 | Filing |
Mar 25, 2025 | 8-K | Current Report |